CHF and arrhythmias:


Palliative therapy to maintain ductus arteriosus patency until corrective or palliative surgery can be performed in neonates with congenital heart defects and who depend on patent ductus for survival.


Not applicable.


Use lowest effective dose for shortest duration. Give by continuous IV infusion into large vein (preferred) or through an umbilical artery catheter placed at the ductal opening. Initially 0.05–0.1mcg/kg/min. Reduce dose from 0.1 to 0.05 to 0.025 to 0.01mcg/kg/min after therapeutic response is achieved to provide lowest dose that maintains response. If inadequate response to 0.05mcg/kg/min; may increase up to 0.4mcg/kg/min.

Boxed Warning:

Apnea in neonates with congenital heart defects; use where ventilatory assistance is immediately available.


Respiratory distress syndrome: not recommended. Bleeding disorders. Prolonged therapy (>120hrs): monitor for antral hyperplasia and gastric outlet obstruction. Monitor respiratory status, arterial pressure, blood oxygenation, BP, blood pH; decrease infusion rate if arterial pressure falls significantly. Neonates <2kg at birth.

Pharmacologic Class:

Prostaglandin E1.


Caution with anticoagulants.

Adverse Reactions:

Apnea, fever, flushing, bradycardia, hypotension, tachycardia, seizures, diarrhea, sepsis, cortical proliferation of the long bones (long-term infusion).

How Supplied:

Ampules (1mL)—5